The Oxford vaccine is more effective in two doses

The Oxford vaccine against corona has been successfully tested in another experiment. Studies have shown that when two doses of their vaccine are administered, stronger antibodies are produced in the animal's body.

The vaccine will hit the market next October. Earlier, there was talk of September. The name of the vaccine is 'AZD1222'. It is being developed jointly with Oxford by the UK pharmaceutical company AstraZeneca. The vaccine was experimentally administered to the human body a couple of months ago to determine its side effects and efficacy. 

Recently applied to the body of pigs. It has been found that strong antibodies are produced in the body of pigs as a result of application of two doses. The first dose is called 'Prime'. And the name of the second dose is 'Boost'. In many viruses, two doses are applied. Measles, rubella and pneumonia vaccines for children are given in two doses.

Vaccines for flu are usually given to pigs before they are marketed. This is because the flu vaccine causes almost the same reaction in pigs and humans. Although 'AZD1222' has been experimentally applied to the human body, its effectiveness has not yet been proven. But in the meantime, AstraZeneca has started mass production of this vaccine. Professor Adrian Hill is one of the scientists involved in creating 'AZD1222'. He said the vaccine could hit the market in October. However, many experts believe that it is not possible to bring any vaccine to the market before 2021.

"I believe the vaccine will provide protection for a year," AstraZeneca's chief executive said earlier. Although there is no scientific evidence for this. Vaccines against other flu-like diseases produce antibodies for a maximum of six months. Source: Daily Mail.